Jpmorgan Chase & CO Seagen Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $29.6 Million - $33.4 Million	154,607 Added 7.36%	2,255,659 $479 Million
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $231 Million - $254 Million	-1,229,548 Reduced 36.92%	2,101,052 $404 Million
Q1 2023 May 18, 2023	BUY	$127.59 - $203.08 $724,328 - $1.15 Million	5,677 Added 0.17%	3,330,600 $674 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $6.65 Million - $10.6 Million	52,134 Added 1.59%	3,324,923 $673 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $28.9 Million - $34.2 Million	245,933 Added 8.13%	3,272,789 $421 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $3.4 Million - $4.53 Million	-25,124 Reduced 0.82%	3,026,856 $414 Million
Q2 2022 Aug 11, 2022	BUY	$108.81 - $179.33 $74.6 Million - $123 Million	685,718 Added 28.98%	3,051,980 $540 Million
Q1 2022 May 11, 2022	SELL	$119.61 - $157.85 $202 Million - $266 Million	-1,686,537 Reduced 41.61%	2,366,262 $341 Million
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $1.24 Million - $1.66 Million	-8,682 Reduced 0.21%	4,052,799 $627 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $579 Million - $690 Million	4,061,481 New	4,061,481 $690 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.